The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 243 results:
Author Title [ Type(Desc)] Year
Filters: Author is Karagiannis, Asterios  [Clear All Filters]
Journal Article
Katsiki, N., Athyros V. G., Karagiannis A., Wierzbicki A. S., & Mikhailidis D. P. (2014).  Should we expand the concept of coronary heart disease equivalents?. Curr Opin Cardiol. 29(4), 389-95.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial.. J Hepatol. 57(2), 476.
Patoulias, D., Manafis A., Mitas C., Avranas K., Lales G., Zografou I., et al. (2018).  Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.. Cardiovasc Hematol Disord Drug Targets. 18(2), 139-146.
Karagiannis, A., Tziomalos K., Papageorgiou A., Kakafika A. I., Pagourelias E. D., Anagnostis P., et al. (2008).  Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.. Expert Opin Pharmacother. 9(4), 509-15.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Stage of chronic kidney disease and severity of coronary heart disease manifestation.. Expert Opin Pharmacother. 13(4), 457-60.
Athyros, V. G., Tziomalos K., Florentin M., Karagiannis A., & Mikhailidis D. P. (2010).  Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. Curr Med Res Opin. 26(4), 839-42.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Statin-fibrate combination for mixed dyslipidaemia: a limited option?. Curr Med Res Opin. 26(9), 2137-40.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Pagourelias E. D., Savvatianos S. D., Elisaf M., et al. (2007).  Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients.. Open Cardiovasc Med J. 1, 8-14.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.. Curr Vasc Pharmacol. 7(3), 264-6.
Athyros, V. G., Karagiannis A., & Mikhailidis D. P. (2010).  Statins and heart failure.. J Am Coll Cardiol. 55(15), 1644-5; author reply 1646.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Statins and nonalcoholic fatty liver disease: a bright future?. Expert Opin Investig Drugs. 22(9), 1089-93.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and non-alcoholic steatohepatitis.. J Hepatol. 64(1), 241-2.
Athyros, V. G., Kakafika A., Karagiannis A., & Mikhailidis D. P. (2007).  Statins and regression of coronary atherosclerosis.. JAMA. 297(20), 2197; author reply 2197.
Athyros, V. G., Karagiannis A., Kakafika A., Elisaf M., & Mikhailidis D. P. (2007).  Statins and renal function. Is the compound and dose making a difference?. Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and Type 2 Diabetes Mellitus: An Update After 1 Year.. Curr Pharm Des. 22(18), 2723-5.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opin Pharmacother. 16(10), 1449-61.
Paraskevas, K. I., Athyros V. G., Briana D. D., Kakafika A. I., Karagiannis A., & Mikhailidis D. P. (2007).  Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures.. Curr Drug Targets. 8(8), 942-51.
Athyros, V. G., Kakafika A. I., Tziomalos K., Papageorgiou A. A., & Karagiannis A. (2008).  Statins for the prevention of first or recurrent stroke.. Curr Vasc Pharmacol. 6(2), 124-33.
Anagnostis, P., Karras S. N., Athyros V. G., Mikhailidis D. P., & Karagiannis A. (2014).  Subclinical Cushing's syndrome and cardiovascular disease.. Lancet Diabetes Endocrinol. 2(5), 361.
Stavropoulos, K., Imprialos K. P., Doumas M., Athyros V. G., & Karagiannis A. (2018).  Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. J Hypertens. 36(3), 701.
Polyzos, S. A., Perakakis N., Boutari C., Kountouras J., Ghaly W., Anastasilakis A. D., et al. (2019).  Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD.. J Clin Endocrinol Metab.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. Curr Vasc Pharmacol. 14(1), 88-97.
Athyros, V. G., Mikhailidis D. P., Papageorgiou A. A., Didangelos T. P., Peletidou A., Kleta D., et al. (2005).  Targeting vascular risk in patients with metabolic syndrome but without diabetes.. Metabolism. 54(8), 1065-74.
Kostapanos, M. S., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Therapeutic options for statin-intolerant patients.. Curr Med Res Opin. 28(3), 345-9.
Mitsiou, E. K., Athyros V. G., Karagiannis A., & Mikhailidis D. I. (2012).  Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?. Open Cardiovasc Med J. 6, 28-32.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.